MedTrace Logo

Elimination of Albumin-Bound Substances by MARS and Prometheus

NCT00407004 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2006-12-04

No results posted yet for this study

Summary

This trial compares the efficacy of two artificial liver support systems, MARS (Molecular Adsorbents Recirculating System) and Prometheus (FPSA, Fractionated Plasma Separation and Adsorption), in removing albumin-bound substances such as bilirubin, bile acids, and cytokines.

Conditions

  • Liver Failure

Interventions

DEVICE

MARS (Molecular Adsorbents Recirculating System)

DEVICE

Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)

Sponsors & Collaborators

  • Fresenius Medical Care North America

    collaborator INDUSTRY

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Rudolf E. Stauber, MD · Medical University of Graz

  • Peter Krisper, MD · Medical University of Graz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Completion
2004-04-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00407004 on ClinicalTrials.gov